369 related articles for article (PubMed ID: 34489966)
1. The Pathophysiology and Treatment of Graft-
Teshima T; Hill GR
Front Immunol; 2021; 12():715424. PubMed ID: 34489966
[TBL] [Abstract][Full Text] [Related]
2. GVHD Prophylaxis 2020.
Gooptu M; Antin JH
Front Immunol; 2021; 12():605726. PubMed ID: 33897681
[TBL] [Abstract][Full Text] [Related]
3. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
4. Treatment with Mesenchymal Stromal Cells Overexpressing Fas-Ligand Ameliorates Acute Graft-versus-Host Disease in Mice.
Vacaru AM; Mazilu AM; Dumitrescu M; Fenyo IM; Gafencu AV; Vacaru AM
Int J Mol Sci; 2022 Jan; 23(1):. PubMed ID: 35008964
[TBL] [Abstract][Full Text] [Related]
5. Graft-versus-host disease prophylaxis: Pathophysiology-based review on current approaches and future directions.
Martinez-Cibrian N; Zeiser R; Perez-Simon JA
Blood Rev; 2021 Jul; 48():100792. PubMed ID: 33386151
[TBL] [Abstract][Full Text] [Related]
6. Graft-vs-host disease following allogeneic hematopoietic cell transplantation.
Pidala J
Cancer Control; 2011 Oct; 18(4):268-76. PubMed ID: 21976245
[TBL] [Abstract][Full Text] [Related]
7. Role of cytokines in the pathophysiology of acute graft-versus-host disease (GVHD): are serum/plasma cytokines potential biomarkers for diagnosis of acute GVHD following allogeneic hematopoietic cell transplantation (Allo-HCT)?
Toubai T; Tanaka J; Paczesny S; Shono Y; Reddy P; Imamura M
Curr Stem Cell Res Ther; 2012 May; 7(3):229-39. PubMed ID: 22023620
[TBL] [Abstract][Full Text] [Related]
8. Defibrotide combined with triple therapy including posttransplant cyclophosphamide, low dose rabbit anti-t-lymphocyte globulin and cyclosporine is effective in prevention of graft versus host disease after allogeneic peripheral blood stem cell transplantation for hematologic malignancies.
Akpinar S; Kayikci O; Tekgunduz E
Transfus Apher Sci; 2022 Feb; 61(1):103367. PubMed ID: 35120825
[TBL] [Abstract][Full Text] [Related]
9. How does transfusion-associated graft-versus-host disease compare to hematopoietic cell transplantation-associated graft-versus-host disease?
Aizawa K; Peltier D; Matsuki E; Toubai T
Transfus Apher Sci; 2022 Apr; 61(2):103405. PubMed ID: 35210194
[TBL] [Abstract][Full Text] [Related]
10. Ocular graft-versus-host disease: a review.
Shikari H; Antin JH; Dana R
Surv Ophthalmol; 2013; 58(3):233-51. PubMed ID: 23541042
[TBL] [Abstract][Full Text] [Related]
11. Preclinical models of acute and chronic graft-versus-host disease: how predictive are they for a successful clinical translation?
Zeiser R; Blazar BR
Blood; 2016 Jun; 127(25):3117-26. PubMed ID: 26994149
[TBL] [Abstract][Full Text] [Related]
12. Defibrotide inhibits donor leucocyte-endothelial interactions and protects against acute graft-versus-host disease.
García-Bernal D; Palomo M; Martínez CM; Millán-Rivero JE; García-Guillén AI; Blanquer M; Díaz-Ricart M; Sackstein R; Carreras E; Moraleda JM
J Cell Mol Med; 2020 Jul; 24(14):8031-8044. PubMed ID: 32519822
[TBL] [Abstract][Full Text] [Related]
13. Mesenchymal Stromal Cells in Pediatric Hematopoietic Cell Transplantation a Review and a Pilot Study in Children Treated With Decidua Stromal Cells for Acute Graft-versus-Host Disease.
Ringdén O; Gustafsson B; Sadeghi B
Front Immunol; 2020; 11():567210. PubMed ID: 33193339
[TBL] [Abstract][Full Text] [Related]
14. Correlation between disparity for the minor histocompatibility antigen HA-1 and the development of acute graft-versus-host disease after allogeneic marrow transplantation.
Tseng LH; Lin MT; Hansen JA; Gooley T; Pei J; Smith AG; Martin EG; Petersdorf EW; Martin PJ
Blood; 1999 Oct; 94(8):2911-4. PubMed ID: 10515896
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic stem cell transplantation as treatment for heavily treated, refractory acute graft-versus-host disease after HLA-mismatched stem cell transplantation.
Ikegame K; Yoshihara S; Taniguchi Y; Kaida K; Inoue T; Okada M; Taniguchi K; Hasei H; Tamaki H; Fujioka T; Kato R; Soma T; Ogawa H
Exp Hematol; 2011 Aug; 39(8):880-90. PubMed ID: 21689724
[TBL] [Abstract][Full Text] [Related]
16. Translational Clinical Strategies for the Prevention of Gastrointestinal Tract Graft
Rayasam A; Drobyski WR
Front Immunol; 2021; 12():779076. PubMed ID: 34899738
[TBL] [Abstract][Full Text] [Related]
17. Acute Graft-Versus-Host Disease: A Brief Review.
Aladağ E; Kelkitli E; Göker H
Turk J Haematol; 2020 Feb; 37(1):1-4. PubMed ID: 31475512
[TBL] [Abstract][Full Text] [Related]
18. Bone marrow transplantation: new approaches to immunosuppression and management of acute graft-versus-host disease.
Auletta JJ; Cooke KR
Curr Opin Pediatr; 2009 Feb; 21(1):30-8. PubMed ID: 19242239
[TBL] [Abstract][Full Text] [Related]
19. Clinical applications for biomarkers of acute and chronic graft-versus-host disease.
Levine JE; Paczesny S; Sarantopoulos S
Biol Blood Marrow Transplant; 2012 Jan; 18(1 Suppl):S116-24. PubMed ID: 22226094
[TBL] [Abstract][Full Text] [Related]
20. T Helper Cell Lineage-Defining Transcription Factors: Potent Targets for Specific GVHD Therapy?
Campe J; Ullrich E
Front Immunol; 2021; 12():806529. PubMed ID: 35069590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
